SCHEMBL5149716

SCHEMBL5149716

COC(=O)c1ccc(OC(OC(C)=O)(C(=O)Cc2ccc(NC(=O)Nc3ccccc3Cl)c(OC)c2)N2CCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 9/20 0.47
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
TP53 P04637 2/20 0.38
MCHR1 Q99705 1/20 0.38
ITGB1 P05556 1/20 0.38
POLB P06746 2/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.38
TSHR P16473 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151532 0.95 ITGA4 (0.50) ITGA4LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5149789 0.93 ITGA4 (0.49) ITGA4LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5153468 0.92 ITGA4 (0.47) ITGA4LMNAMAPTKMT2AGAA
SCHEMBL5151565 0.88 ITGA4 (0.57) ITGA4LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5153501 0.88 ITGA4 (0.49) ITGA4LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5153490 0.87 ITGA4 (0.51) ITGA4LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5154997 0.86 ITGA4 (0.49) ITGA4LMNAMAPTKMT2AGAA
SCHEMBL5152052 0.85 ITGA4 (0.51) ITGA4LMNAMAPTKMT2AGAA
SCHEMBL5151631 0.85 ITGA4 (0.48) ITGA4LMNAMAPTKMT2AGAA
SCHEMBL5151954 0.84 ALDH1A1 (0.45) ITGA4LMNASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 ITGA4 4/4885LMNA 2312/4885SMN1; SMN2 4245/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 ITGA4 5/4885LMNA 2327/4885SMN1; SMN2 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.